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Letter to Editor
Platelet transfusion: from empiricism
to scientific evidence
REVISTA BRASILEIRA
DE HEMATOLOGIA
E  H E M O T E R A P I A
Dear Editor,
The progress in diagnosis and treatment of onco-
hematological diseases has been amply demonstrated. The
transfusions of packed red blood cells (CH) and platelet
concentrates have important roles in ensuring increased survival
and cure rates in these patients. At the same time, there is a
consensus about the development of Brazilian hemotherapy, in
particular, highlighted by increased and improved scientific
production.
Even with the advances in this area, the study of
immunohematology of erythrocytes, fundamental to transfusion
safety, remains one of the most sensitive and vulnerable links in
the blood transfusion system as the tests are performed at the end
of the system in transfusion agencies (TA) that are often isolated
in small hospitals or towns. Despite knowledge on erythrocyte
immunohematology being available for more than 100 years and
being duly regulated by Brazilian transfusion legislation,(1) we still
see today nonconformities in the implementation of pre-
transfusion testing that can affect the transfusional safety of packed
red blood cells. This was observed in a soon-to-be-released study
designed to evaluate the effectiveness of TA in the state of Minas
Gerais (Moraes-Souza H, personal communication).
Thus, the mandatory employment of easy-to-use
immunohistochemical techniques to test erythrocytes(1) has resulted
in marked reductions in rates of alloimmunization in patients
submitted to multiple transfusions of packed red blood cells.(2) On
the other hand, Brazilian legislation does not rule in regards to the
effectiveness of platelet concentrate transfusions and platelet
immunohematology. And, while the international literature reports
high refractoriness and alloimmunization rates in platelet
transfusions,(3) little has been published in Brazil on this subject,(4,5)
with the use of platelet transfusions being surrounded by
empiricism.
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The emphasis given this subject at the last Brazilian
Hematology Congress (HEMO 2009) – through pre-congress
courses, conferences and round tables – was significantly higher
than in previous years. However, there was not the same
reverberation in the scientific production; of the 1216 abstracts
submitted, only five (0.41%) were related to this topic: quality
control of platelet concentrates, platelet refractoriness, clinical
indication, alloimmunization and HPA (Human Platelet Antigen)
genotyping.(6) One study, undertaken in our service, found a poor
platelet increment of 50% and platelet refractoriness in 20% of
cases (Ferreira, AA, personal communication).
In light of current knowledge and taking into account the
successful experience of America and European countries,(7) we
believe that a little more commitment of the scientific community,
blood transfusion services and Brazilian health authorities will be
sufficient to change this disturbing scene. There are more than one
million Brazilians registered in the National Registry of Bone
Marrow Donors (Radome), many of whom are loyal blood donors.
With the consent of these blood and bone marrow donors, why
are their HLA (Human Leukocyte Antigen) typing results not
available to blood transfusion services? Surely this would further
validate public investments in HLA typing of blood donors, who
are also candidates for bone marrow donation, as a tiny portion of
these actually result in marrow donation.
Whereas approximately 80% of platelet alloimmunizations
are due to HLA class I antigens, Brazil will have one of the
largest genotyped platelet donor banks. In pursuit of excellence
in transfusion medicine and, above all, efficiency, it is also
essential to standardize techniques of HPA genotyping and
immunophenotyping. The training of regional reference centers
is essential.
Therefore protocols for the proper identification of platelet
refractoriness and selection of donors should be proposed and
implemented urgently to guide the physician in the most
appropriate clinical conduct with effective treatment aimed at
validating the use of platelet concentrates. Attaining this goal will
not only increase the safety of platelet transfusions, but will place
Brazil on the same level of the so-called developed countries with
regards to transfusion medicine.
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